Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
NS Pharma
Marketing
Evidence pushes back on FDA's use of surrogate markers: report
A recent report shows that there is little evidence backing the FDA's use of surrogate markers to determine if a medicine is fit for approval.
Kevin Dunleavy
May 29, 2024 11:25am
NS Pharma's Duchenne drug Viltepso flunks confirmatory trial
May 28, 2024 11:54am
NS Pharma launches ‘Duchenne Heroes’ campaign
Nov 27, 2023 10:08am
FDA signs off on Santhera's muscular dystrophy drug Agamree
Oct 27, 2023 8:23am
AstraZeneca, Takeda, Samsung Biologics and more—FiercePharmaAsia
Aug 14, 2020 9:18am
NS Pharma Duchenne drug wins speedy FDA nod to challenge Sarepta
Aug 13, 2020 11:34am
